Albemarle - ALB Stock Forecast, Price & News

18 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Albemarle in the last twelve months. There are currently 2 sell ratings, 7 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ALB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALB, but not buy additional shares or sell existing shares.
View ALB analyst ratings or view top-rated stocks.

18 Wall Street analysts have issued 1 year price objectives for Albemarle's stock. Their ALB share price forecasts range from $155.00 to $497.00. On average, they anticipate the company's share price to reach $299.37 in the next twelve months. This suggests a possible upside of 7.2% from the stock's current price.
View analysts price targets for ALB or view top-rated stocks among Wall Street analysts.

Albemarle's stock was trading at $216.86 at the beginning of the year. Since then, ALB stock has increased by 28.8% and is now trading at $279.34.
View the best growth stocks for 2023 here.

Albemarle saw a increase in short interest during the month of December. As of December 30th, there was short interest totaling 3,400,000 shares, an increase of 18.9% from the December 15th total of 2,860,000 shares. Based on an average daily volume of 1,490,000 shares, the short-interest ratio is currently 2.3 days.
View Albemarle's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 15th 2023.
View our ALB earnings forecast.

Albemarle will be holding an earnings conference call on Thursday, February 16th at 9:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 866-813-9403 with passcode "384178".

Albemarle Co. (NYSE:ALB) issued its earnings results on Wednesday, November, 3rd. The specialty chemicals company reported $1.05 earnings per share for the quarter, beating analysts' consensus estimates of $0.77 by $0.28. The specialty chemicals company earned $830.57 million during the quarter, compared to analysts' expectations of $775.61 million. Albemarle had a trailing twelve-month return on equity of 26.84% and a net margin of 27.77%. During the same quarter in the prior year, the firm posted $1.09 EPS.
Read the conference call transcript.

Albemarle declared a quarterly dividend on Monday, October 24th. Stockholders of record on Friday, December 16th will be given a dividend of $0.395 per share on Tuesday, January 3rd. This represents a $1.58 annualized dividend and a dividend yield of 0.57%. The ex-dividend date is Thursday, December 15th.
Read our dividend analysis for ALB.

Albemarle (NYSE:ALB) pays an annual dividend of $1.58 per share and currently has a dividend yield of 0.55%. The company has been increasing its dividend for 29 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 11.98%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, ALB will have a dividend payout ratio of 5.63% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for ALB.

Albemarle updated its FY23 earnings guidance on Monday, January, 23rd. The company provided EPS guidance of $26.00-33.00 for the period, compared to the consensus EPS estimate of $28.23. The company issued revenue guidance of $11.30-12.90 billion, compared to the consensus revenue estimate of $10.02 billion.

63 employees have rated Albemarle Chief Executive Officer Luther C. Kissam, IV on Glassdoor.com. Luther C. Kissam, IV has an approval rating of 75% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Albemarle investors own include Intact Financial (IFC), Constellation Software (CSU), AutoCanada (ACQ), Alimentation Couche-Tard (ATD.B), AbbVie (ABBV), Vermilion Energy (VET), Wheaton Precious Metals (WPM), NVIDIA (NVDA), Rogers Communications (RCI) and Alibaba Group (BABA).

Albemarle trades on the New York Stock Exchange (NYSE) under the ticker symbol "ALB."

Albemarle's stock is owned by a number of retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (2.31%), International Assets Investment Management LLC (1.20%), Robeco Schweiz AG (0.74%), ProShare Advisors LLC (0.54%), Sumitomo Mitsui Trust Holdings Inc. (0.32%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Eric Norris, J Kent Masters, John Clarence Barichivich III, Karen G Narwold, Karen G Narwold, Luther C Iv Kissam, Netha N Johnson, Raphael Goszcz Crawford and Scott Tozier.
View institutional ownership trends.

Shares of ALB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ALB stock can currently be purchased for approximately $279.34.

Albemarle (NYSE:ALB) has a market capitalization of $32.72 billion and generates $3.33 billion in revenue each year. The specialty chemicals company earns $123.67 million in net income (profit) each year or $13.19 on an earnings per share basis.

The company employs 6,000 workers across the globe.

Albemarle's mailing address is 4250 CONGRESS STREET SUITE 900, CHARLOTTE NC, 28209. The official website for the company is www.albemarle.com. The specialty chemicals company can be reached via phone at (980) 299-5700, via email at invest@albemarle.com, or via fax at 225-388-7686.